GlobeNewswire by notified

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

Share

PRESS RELEASE

November 23, 2020

  • Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.
  • Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period.
  • Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.
  • Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 2020, at 2:00pm ET / 20.00 CET.

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced positive top-line results from the Phase 2 open-label extension study of Tesomet in patients with hypothalamic obesity (HO). Patients treated with Tesomet for nearly one year (24 week double-blind [DB] followed by 24 week open label extension [OLE]) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. No clinically meaningful differences in heart rate or blood pressure were observed over the course of the trial.

“Hypothalamic obesity is a rare disorder characterized by severe and debilitating obesity that is often complicated by depression, impulse control issues, complicated symptoms from necessary replacement of pituitary hormones, and increased risk of cardiometabolic disorders. There are no treatments specifically approved for HO, and standard weight loss approaches such as surgery, medication and lifestyle counseling are mostly ineffective in this rare disease,” said Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital and Principal Investigator on the Phase 2 study. “The data from this nearly year-long study demonstrate the potential of Tesomet to help manage multiple key symptoms of HO – not only weight gain but also the metabolic dysfunction that can lead to serious diabetic complications. I look forward to the evaluation of Tesomet in further clinical studies.”

“The results of the open-label extension study reinforce the promising profile of Tesomet observed in the placebo-controlled portion of the Phase 2 study in patients with hypothalamic obesity,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development of Saniona. “If approved, Tesomet could be the first treatment designed to address this rare disease. We look forward to continuing our discussions with the FDA and clarifying the path to bring Tesomet to the HO patients who desperately need treatment options.”

Highlights from top-line open-label extension study data include:

  • Safety: The primary endpoint of the study was the overall safety and tolerability of Tesomet in patients with HO. Tesomet was shown to be well-tolerated. Side effects observed in the open-label extension (OLE) period of the study were generally mild and consistent with those observed in the double-blind (DB) period. The most common adverse events included dry mouth, joint pain, headache and dizziness. There were three events of palpitations in the placebo patients who were switched to Tesomet, and none in the group that received Tesomet for the full 48 weeks. There was one serious adverse event related to abdominal pain which spontaneously resolved. There were no clinically meaningful differences in heart rate or blood pressure observed over the nearly year-long study. All 18 patients who entered the OLE study completed it.
  • Bodyweight: As previously reported, treatment with Tesomet led to a statistically significant 6.28% average reduction in bodyweight compared to placebo (p=0.0169) in the 24-week DB period of the study. This reduction was maintained through the 24-week OLE period, with these patients demonstrating a statistically significant 5.96% average reduction in bodyweight at Week 48 (p=0.008 vs baseline). Additionally, patients who received placebo during the DB period and were switched to Tesomet at Week 24 for the OLE period demonstrated a clinically meaningful 4.95% average reduction in bodyweight from baseline to Week 48.
  • Waist circumference: As previously reported, treatment with Tesomet led to a 5.04% reduction in waist circumference compared to placebo (p=0.0519) in the DB period. This reduction was maintained during the OLE period, with these patients demonstrating a 5.07% reduction in waist circumference at Week 48 (p=0.003). Additionally, patients who received placebo during DB period and were switched to Tesomet at Week 24 for the OLE period demonstrated a 2.24% average reduction in waist circumference from baseline to Week 48.
  • Glycemic control: As previously reported, there were two diabetic (T2D) patients who received Tesomet during the DB period, and they showed marked reduction of HbA1c levels (48.8% at Week 24), while no change was seen in normoglycemic patients. These two diabetic patients continued to receive Tesomet during the OLE period, and the reduction in HbA1c was maintained (46.17% at Week 48).

Saniona intends to present and/or publish additional data from this study in an appropriate future peer-reviewed, scientific forum. Additionally, Saniona intends to provide these data to the FDA as part of ongoing communications around plans to ensure that only appropriate patients would receive Tesomet, if approved. Pending this alignment with the FDA, Saniona intends to initiate a Phase 2b study in HO in the first half of 2021.

About the Phase 2 Study
This randomized, double-blind, placebo-controlled Phase 2 study evaluated Tesomet administered daily in patients with HO. The primary endpoint of the study was overall safety and tolerability measured by all safety data collected during the study including recorded adverse events, laboratory data, blood pressure, and heart rate. The secondary efficacy endpoints included bodyweight, waist circumference, glycemic control and other measures. In the double-blind (DB) period of the study, patients received either Tesomet or matching placebo (2:1 randomization) for 24 weeks. A total of 21 patients (13 Tesomet, 8 placebo) were included within the modified intent-to-treat analysis pertaining to the DB period. Top-line results from the DB period were announced in a press release in April 2020.

All 18 patients who completed the DB period of the study were provided the opportunity to receive Tesomet in an open-label extension (OLE) period of the study for an additional 24 weeks. All 18 patients chose to participate in the OLE period, and all patients completed the OLE period. Patients entering the OLE were 83.3% female and on average 44.9 years old, weighing 110.4 kg (243 lbs) with a BMI of 37.2 kg/m2. Further details about the trial can be found at ClinicalTrials.gov.

Webcast
Saniona will host a webcast in which Dr. Feldt-Rasmussen will review the data from this study on Tuesday, 24 November 2020, at 2:00pm ET / 20.00 CET. A live webcast of the presentation can be accessed via: https://edge.media-server.com/mmc/p/33xc2m4t. Subsequently, the event will be archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/.

For more information, please contact
Trista Morrison, Chief Communications Officer. Office + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:00 CET on November 23, 2020.  

About Saniona
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with several companies. Saniona is based in Copenhagen, Denmark, and in Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

About Tesomet
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

About Hypothalamic Obesity (HO)
Hypothalamic obesity (HO) is a rare disorder characterized by intractable weight gain and uncontrollable hunger. Additional symptoms may include memory impairment, attention deficit, impulse control and depression as well as increased risk of cardiovascular and metabolic disorders. Currently, there is no cure for this condition. Treatments used for general weight management such as surgery, medication and lifestyle counseling are often tried in HO, but are mostly ineffective, and there are no medications specifically approved for HO. HO is caused by damage to the hypothalamus, most commonly sustained during surgery to remove a rare, noncancerous tumor called a craniopharyngioma. This tumor can occur at any age, but is most common in children and older adults, creating a burden for both patients and families. HO occurs in approximately one out of every 50,000 to 100,000 people.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea 7 S.A. - Seaway7 awarded contract offshore Poland28.3.2024 17:15:00 CET | Press release

Luxembourg – 28 March 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award to Seaway7, part of the Subsea7 Group, of a sizeable¹ contract by PGE Polska Grupa Energetyczna and Ørsted for the transport and installation of the substations for the Baltica 2 wind farm, offshore Poland. Seaway7’s scope includes the transport and installation of four substations. Offshore activity is scheduled to take place in 2026 utilising both our heavy lift and heavy transportation vessels. Baltica 2 is a 50:50 joint venture between PGE Polska Grupa Energetyczna and Ørsted. The wind farm, with a capacity of around 1.5 GW, will be located in the Polish sector of the Baltic Sea around 40 kilometres from shore at its closest point. Maria Eidesvik, VP for Europe and US at Seaway7 said: “This is our second contract award in the emerging Polish market and we are pleased to be taking a role in developing offshore wind in this key location. With this project we also look forward to continu

Meltwater partners with leading digital agency Social Factor28.3.2024 17:00:00 CET | Press release

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Meltwater, a leading global provider of media, social and consumer intelligence, today announces a new partnership with Social Factor, a global digital agency focusing on social CRM and strategy. With this partnership, Meltwater and Social Factor customers will be able to leverage the best of Meltwater’s social analytics and social media management solutions alongside Social Factor’s specialization in social media operations and community management. Social Factor helps enterprise-level clients turn digital chaos into human connection through content moderation, community management, analytical data, governance, training, and security. They have deep expertise working with innovative technology solutions to foster customer engagement on behalf of Fortune 500 companies and other large, global enterprises. The Meltwater social listening and social media management solutions help teams to stay on top of conversations about their company, i

International Petroleum Corp. Annual General Meeting to be held on May 8, 202428.3.2024 17:00:00 CET | Press release

International Petroleum Corporation (“IPC” or the “Corporation”) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that its Annual General Meeting (the “Meeting”) of holders of common shares (“Shareholders”) will be held at the offices of Blake, Cassels and Graydon LLP, Suite 3500, 855 - 2nd Street S.W., Calgary, Alberta, Canada T2P 4J8 on Wednesday, May 8, 2024 at 8:00 a.m. (Mountain time), for the following purposes: To receive the audited consolidated financial statements of the Corporation for the financial year ended December 31, 2023 and accompanying report of the auditor;To set the number of directors of the Corporation at eight;To elect the eight nominees of the Corporation standing for election as directors of the Corporation to hold office until the next annual meeting of Shareholders or until his or her successor is duly elected or appointed;To appoint PricewaterhouseCoopers SA, as the auditor of the Corporation, to hold office until the next annual meeting of Shareholder

SOFTSWISS Unveils South African iGaming Market Overview28.3.2024 16:52:00 CET | Press release

South Africa’s iGaming market is on a remarkable growth trajectory, set to reach a total revenue of approximately EUR 64.9 million by 2028. SOFTSWISS, a leading iGaming software provider with 15 years of experience, shares the South African market report. GZIRA, Malta, March 28, 2024 (GLOBE NEWSWIRE) -- In light of the recent acquisition of Turfsport, a leading South African provider of wagering solutions, the SOFTSWISS report offers first-hand practical experience. The piece explores peculiarities distinguishing South Africa, including provincial licensing, sports betting, and gaming preferences. Provincial Licensing Online gambling in South Africa is governed by nine provincial regulatory bodies which operate under the National Gambling Board’s framework. Each body is responsible for licensing various gambling activities, including online sports betting, in their provinces. Christian Neuberger, CEO at Turfsport, adds: “While national legislation continues prohibiting interactive gami

Chief People Officer, Amy Hanlon-Rodemich to leave Nokia28.3.2024 15:15:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 16:15 EET Chief People Officer, Amy Hanlon-Rodemich to leave Nokia Espoo, Finland – Nokia today announces that its Chief People Officer, Amy Hanlon-Rodemich, will leave the company and step down from its Group Leadership Team. A recruitment process will begin immediately for her successor and Amy will retain an advisory role during her notice period. Amy joined Nokia in 2022 and has been key to renewing the company’s people services and employee experience. “This has been a difficult decision for me to take. I’ve enjoyed my time at Nokia and am looking forward to the next chapter in my career. I wish everyone at Nokia continued success,” commented Amy. “I would like to thank Amy for her contributions to Nokia and leadership of the People organisation. I wish her all the best with her future endeavours,” said Pekka Lundmark, President and CEO of Nokia. Lorna Gibb, Vice President, Labor & Employment, will assume the role of interi

HiddenA line styled icon from Orion Icon Library.Eye